Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK111 in Moderate-to-Severe Plaque Psoriasis (Phase II)
CTR20210490Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of gumokimab in plaque psoriasis, sponsored by Akeso, Inc.. Started Mar 2021; status: completed.
02
Drugs
gumokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20210490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210490.